Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3905980 | 0.81 | MAPT (0.48) | MAPK1NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL3905983 | 0.81 | MAPT (0.48) | MAPK1NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL13537540 | 0.72 | KMT2A (0.43) | MAPK1NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL23793685 | 0.71 | MAPT (0.45) | MAPK1NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL13899728 | 0.71 | MAPK1 (0.75) | MAPK1NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL13537423 | 0.71 | MAPK1 (0.36) | MAPK1NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL6086787 | 0.71 | MAPT (0.46) | MAPK1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL14574219 | 0.69 | MAPT (0.44) | MAPK1NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL6081224 | 0.69 | KMT2A (0.56) | MAPK1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3904192 | 0.68 | PLK1 (0.50) | MAPK1ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
| CN-1649853-A | Thiazolidinones compound, its preparing method and use as medicine | SCHERING AG (DE) | 2005-08-03 | — | — | CN | disclosed |
| EP-1501794-A1 | THIAZOLIDINONES AND THE USE THEREOF AS POLO-LIKE KINASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093249-A1 | THIAZOLIDINONES AND THE USE THEREOF AS POLO-LIKE KINASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | MAPK1 1221/4885NPSR1 4260/4885ALDH1A1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.